European risk factors' model to predict hospitalization of premature infants born 33–35 weeks' gestational age with respiratory syncytial virus: validation with Italian data

References

• Simões EA. RSV disease in the pediatric population: epidemiology, seasonal variability, and long-term outcomes. Managed Care 2008;17:3–6.
   Google Scholar
• Medici MC, Arcangeletti MC, Rossi GA, Lanari M, Merolla R, Paparatti UDL, Chezzi1 C, on behalf of the “Osservatorio VRS Study” Group. Four-year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the “Osservatorio VRS” Study (2000-2004). The New Microbiologica 2006;29:35–43.
   PubMed Web of Science ®Google Scholar
• Welliver RC. Review of epidemiology and clinical risk factors for severe respiratory syncytial virus (RSV) infection. J Pediatr 2003;143:S112–S117.
   PubMed Web of Science ®Google Scholar
• Horn SD, Smout RJ. Effect of prematurity on respiratory syncytial virus hospital resource use and outcomes. J Pediatr 2003;143(5 Suppl): S133–S141.
   PubMed Web of Science ®Google Scholar
• Sampalis JS. Morbidity and mortality after RSV-associated hospitalizations among premature Canadian infants. J Pediatr 2003;143:S150–S156.
   PubMed Web of Science ®Google Scholar
• Feltes TF, Cabalka AK, Meissner C, Piazza FM, Carlin DA, Top FH, Connor EM, Sondheimer HM for Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003;143:532–540.
   PubMed Web of Science ®Google Scholar
• Simões EAF. Immunoprophylaxis of respiratory syncytial virus: global experience. Respiratory Res 2002;3(Suppl 1): S26–S33.
   PubMed Web of Science ®Google Scholar
• Impact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531–537.
   Web of Science ®Google Scholar
• Rondini G, Macagno F, Barberi I. Raccomandazioni della Società Italiana di Neonatologia per la prevenzione delle malattie da virus respiratorio sinciziale (VRS). Acta Neonantologica 2004;1:1–11.
   Google Scholar
• Simões EAF, Carbonell-Estrany X, Fullarton JR, Liese JG, Figueras-Aloy J, Doering G, Guzman J, European RSV Risk Factor Study Group. A predictive model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33–35 weeks of gestational age, based on data from the Spanish FLIP study. Respiratory Res 2008;9:78.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero J. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalisation in premature infants born at a gestational age of 33–35 weeks in Spain. Pediatr Infect Dis J 2004;23:815–820.
   PubMed Web of Science ®Google Scholar
• Fisher RA. The use of multiple measurements in taxonomic problems. Ann Eugenics 1936;7:179–188.
   Google Scholar
• Lanari M, Giovanni M, Giuffré L, Marini A, Rondini G, Rossi A, Merolla R, Zuccotti GV, Salvioli GP, Investigators R.A.DA.R. Study Group. Prevalence of respiratory syncytial virus infection in Italian infants hospitalised for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity. Pediatr Pulmonol 2002;33:1–8.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UL, Silvestri M, Pistorio A, Chezzi C, Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007;166:1267–1272.
   PubMed Web of Science ®Google Scholar
• Liese JG, Grill E, Fischer B, Roeckl-Wiedmann I, Carr D, Belohradsky BH; The Munich RSV Study Group. Incidence and risk factors of respiratory syncytial virus-related hospitalizations in premature infants in Germany. Eur J Pediatr 2003;162:230–236.
   PubMed Web of Science ®Google Scholar
• Rossi GA, Medici MC, Merollo R; the “Osservatorio VRS” Study Group. Incidence of respiratory syncytial virus positivity in young Italian children referred to the emergency departments for lower respiratory tract infection over two consecutive epidemic seasons. Infection 2005;33:18–24.
   PubMed Web of Science ®Google Scholar
• SPSS Inc. 444 N. Michigan Avenue, Chicago, IL 60611.
   Google Scholar
• Altman DG, Bland JM. Diagnostic tests 2: predictive values. Statistical notes. BMJ 1994;309:102.
   PubMed Web of Science ®Google Scholar
• Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. Statistical notes. BMJ 2004;329:168–169.
   PubMed Web of Science ®Google Scholar
• Law BJ, Langley JM, Allen U, Paes B, Lee DSC, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, et al The pediatric investigators collaborative network on infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004;23:806–814.
   PubMed Web of Science ®Google Scholar
• Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Coménech-Martinez E for the IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008;27:788–793.
   PubMed Web of Science ®Google Scholar
• Wang D, Cummins C, Bayliss S. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation. Health Technology Assess 2008;12:(36).
   Web of Science ®Google Scholar
• Navér L, Eriksson M, Ewald U, Linde A, Lindroth M, Schollin J. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden. Acta Pediatr 2004;93:1470–1473.
   PubMed Web of Science ®Google Scholar
• Chirico G, Ravasio R, Sbarigia U. Cost-utility analysis of palivizumab in Italy: results from a simulation model in the prophylaxis of respiratory syncytial virus infection (RSV) among high-risk preterm infants. Italian J Pediatr 2009;35:4.
   PubMed Web of Science ®Google Scholar